Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
139.8 USD | +0.56% | -0.21% | +5.90% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 57% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- With an expected P/E ratio at 33.36 and 21.93 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+5.51% | 13.99B | C+ | ||
+2.93% | 108B | B+ | ||
-5.01% | 23.46B | B | ||
-14.60% | 21.72B | B+ | ||
-7.05% | 18.64B | A- | ||
-38.55% | 17.45B | A- | ||
-8.83% | 17.19B | B | ||
+37.49% | 12.53B | C+ | ||
+329.39% | 8.81B | - | D+ | |
-24.02% | 8.32B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NBIX Stock
- Ratings Neurocrine Biosciences, Inc.